跳至主要内容
临床试验/NCT02293525
NCT02293525撤回不适用

Investigational Plan for the Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain

Vital 5, LLC0 个研究点开始时间: 2014年11月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
发起方
主要终点
Pain (Mean VAS pain score at 24 hours post-procedure)

研究概览

简要总结

The purpose of this study is to evaluate the clinical performance of the ReLeaf infusion catheter & wound drain in patients following lumbar spinal fusion surgery. One half of the patients will receive continuous local analgesic fusion during the post-operative period while the other half will received continuous local saline.

详细描述

Posterior lumbar spinal fusion is commonly used in the management of a wide array of spinal disorders ranging from instability to degenerative disc disease. However, severe postoperative pain is a significant adverse outcome in patients who have undergone a lumbar spinal fusion procedure. This pain may delay mobilization and decrease compliance with physical, occupational, or pulmonary physiotherapy.

Pain symptoms may worsen with activity and ambulation due to reflex spasms of the paraspinal muscles elicited by pain from the wound. A local anesthetic agent administered immediately after surgery into the tissue surrounding the wound addresses the pain source for less than four hours. Therefore, it is reasonable to consider continuous local anesthetic infusion, which may limit local pain mediators for a longer duration.

Continuous local anesthetic infusion into the paraspinal musculature with the ReLeaf catheter has the potential to reduce pain, narcotic demand & usage, and accelerate the rate of recovery in lumbar spinal fusion patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Skeletally mature
  • Diagnosis of lumbar spine disease requiring an open, midline, instrumented posterolateral fusion with or without interbody support at one or two vertebral levels and laminectomy or laminotomy
  • Physically and mentally willing to comply with the study requirements
  • Signed the study informed consent

排除标准

  • Lumbar spine disease requiring more than two levels of instrumentation
  • Any previous operative lumbar procedure, except discectomy or hemi-laminotomy performed a minimum of 2 years prior to current study surgery
  • Patients requiring iliac crest bone graft for the procedure
  • Intra-operative durotomy
  • Any duration of pre-operative morphine or morphine equivalent use exceeding 30 mg of morphine equivalents per day for longer than 3 months
  • Physically or mentally compromised (i.e., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease, presence of alcohol or substance abuse)
  • Diagnosed with Severe Depression and on treatment
  • Active infection at the operative level or a symptomatic infection
  • Diagnosed systemic disease that would affect the subject's welfare or overall outcome of the research study (i.e. Paget's disease, renal osteodystrophy, Lupus etc)
  • Is pregnant or breast feeding
  • Has any active malignancy or spinal arthrodesis being performed for a tumor decompression
  • Has a known allergy to local analgesics
  • Pending litigation related to back pain or injury or Worker's Compensation

研究组 & 干预措施

Ropivacaine

Active Comparator

Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)

干预措施: Morphine (Drug)

Ropivacaine

Active Comparator

Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)

干预措施: ReLeaf catheter (Device)

Ropivacaine

Active Comparator

Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)

干预措施: Ropivacaine (Drug)

Ropivacaine

Active Comparator

Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)

干预措施: Oxycodone (Drug)

Saline

Placebo Comparator

Continuous saline infusion until catheter removal (typically 36 hours)

干预措施: ReLeaf catheter (Device)

Saline

Placebo Comparator

Continuous saline infusion until catheter removal (typically 36 hours)

干预措施: Saline (Drug)

Saline

Placebo Comparator

Continuous saline infusion until catheter removal (typically 36 hours)

干预措施: Morphine (Drug)

Saline

Placebo Comparator

Continuous saline infusion until catheter removal (typically 36 hours)

干预措施: Oxycodone (Drug)

结局指标

主要结局

Pain (Mean VAS pain score at 24 hours post-procedure)

时间窗: 24 hours

Mean VAS pain score at 24 hours post-procedure

次要结局

  • Adverse Events(3 months)
  • Medication Use(3 months)

研究者

发起方
Vital 5, LLC
申办方类型
Industry
责任方
Sponsor

相似试验

Clinical Evaluation of the ReLeaf Analgesic Infusion... | 临床试验